8-K: Calidi Biotherapeutics Amends Convertible Promissory Notes, Adjusting Conversion Terms

Calidi Biotherapeutics has amended the terms of two convertible promissory notes, adjusting the conversion price and mandatory conversion conditions.

Summary

• Calidi Biotherapeutics amended two convertible promissory notes originally issued on March 8, 2024.
• The amendments adjust the conversion price to an initial price for 180 days, then a reset price based on 94% of the 10-day VWAP.
• Mandatory conversion of the notes is triggered by a financing of at least $8 million in a registered offering or $2 million with a non-affiliated purchaser at 150% of the initial conversion price.
• The company is required to file a registration statement for the resale of shares within five business days after 180 days from the note issuance.

Sentiment

Score: 6

Explanation: The document reflects a standard financial transaction with both positive and negative implications. The amendments provide clarity but also introduce potential dilution risks. The sentiment is neutral to slightly positive.

Positives

• The amendments provide clarity on the conversion terms for the promissory notes.
• The reset conversion price mechanism may be beneficial to the company if the stock price declines.
• The mandatory conversion terms provide a clear path for the notes to convert into equity.

Negatives

• The reset conversion price could result in more shares being issued if the stock price declines.
• The mandatory conversion could dilute existing shareholders if triggered.
• The company is obligated to file a registration statement which may incur costs.

Risks

• The company's stock price could be negatively impacted if the reset conversion price results in a significant increase in shares.
• The mandatory conversion could lead to dilution of existing shareholders.
• The company may face challenges in completing a financing that triggers the mandatory conversion.

Future Outlook

The company is required to file a registration statement within five business days after the 180th day from the issuance of the notes, and the notes may be subject to mandatory conversion upon completion of a qualifying financing.

Management Comments

• The company has entered into amendments to the convertible promissory notes.

Industry Context

The use of convertible notes is a common financing method for biotech companies, especially those in early stages of development. The amendments reflect a negotiation between the company and the investor to adjust the terms of the notes.

Comparison to Industry Standards

• The use of a VWAP-based reset conversion price is a common mechanism to protect investors from significant price declines.
• The mandatory conversion feature is also a standard term in convertible notes, designed to facilitate the conversion of debt into equity upon certain milestones.
• The specific terms, such as the 94% discount and the 150% financing trigger, are specific to this agreement and would need to be compared to similar deals to assess their favorability.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into equity.
• The company's financial position may be strengthened by the potential financing.
• The note holders will have the opportunity to convert their debt into equity.

Next Steps

• The company needs to file a registration statement within five business days after the 180th day from the issuance of the notes.
• The company may need to complete a financing to trigger the mandatory conversion of the notes.

Key Dates

Keywords

convertible notes, promissory notes, conversion price, mandatory conversion, financing, registration statement, VWAP, equity, dilution